The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Tonix Pharmaceuticals and Kemri Partner to Develop Mpox Vaccine
Nov 19, 2024•over 1 year ago
Contract Type
partnership
Chatham
Description
Tonix Pharmaceuticals Holding Corporation has announced a research partnership with the Kenya Medical Research Institute (Kemri) to develop and test a single-dose vaccine for Mpox. The project, worth Sh233.1 million, aims to undertake Phase I clinical trial of TNX-801 in Kenya, focusing on assessing the vaccine’s safety, tolerability and immunogenicity.
Company Information
Company
Tonix Pharmaceuticals Holding Corp
Location
Chatham, Georgia, United States
About
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases.
Predictive Intelligence
Strategic
ML-powered predictions for Tonix Pharmaceuticals Holding Corp's next move
Chatham